Using mice that had been induced with chronic GVHD, researchers administered adMSCs into the eyes via a single injection. Over three weeks, the researchers found that the adMSC treatment increased regulatory T cells while reducing inflammation in the mice. Further, adMSC-conditioned media enhanced cell migration and proliferation in laboratory scratch tests, showcasing the regenerative capacity of the cells. Importantly, the injected cells disappeared within a week, minimizing the risk of long-term complications such as tumor formation.
“Our findings highlight the dual benefits of adMSCs: They suppress inflammation and enhance tissue healing,” elaborates Dr. Shimmura, senior author and researcher. Adding further, he says, “This makes them a promising candidate for treating immune-related ocular disorders without systemic side effects.”
Dr. George graduated from M.I.T., received his medical degree from Duke University, and earned a Ph.D. from Duke in the field of ocular physiology.
I'm not suggesting that a stem cell guy and an eye guy are doing anything- just found it interesting.
Probably best to ignore the noise until the CC on Thursday, might play a game of poster's word bingo.
1- Plummet 2- Yacht 3- Told the wife 4- I am the wife 5- I've got that sinking feeling 6- Sack the Ceo 7- Just bought more 8- I'm out until after the Cc 9-You are now on ignore 10- I'm still here, idiot
Reg
MSB Price at posting:
$2.66 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)